Vivoryon Therapeutics NV (LTS:0R3M) Total Liabilities: €2.79 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0R3M Vivoryon Therapeutics NV LTS:0R3M
33 GF Score
Price €1.21
! 2 Warning Signs
View Full Analysis

What is Vivoryon Therapeutics NV Total Liabilities?

Vivoryon Therapeutics NV LTS:0R3M +0.84% 33 Total Liabilities is €2.79 Mil as of Dec. 2025. GuruFocus rates LTS:0R3M with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

Vivoryon Therapeutics NV's Total Liabilities for the quarter that ended in Dec. 2025 was €2.79 Mil.

Vivoryon Therapeutics NV's quarterly Total Liabilities declined from Dec. 2024 (€3.40 Mil) to Jun. 2025 (€3.24 Mil) and declined from Jun. 2025 (€3.24 Mil) to Dec. 2025 (€2.79 Mil).

Vivoryon Therapeutics NV's annual Total Liabilities declined from Dec. 2023 (€4.55 Mil) to Dec. 2024 (€3.40 Mil) and declined from Dec. 2024 (€3.40 Mil) to Dec. 2025 (€2.79 Mil).

Vivoryon Therapeutics NV Total Liabilities Historical Data

* Premium members only.

The historical data trend for Vivoryon Therapeutics NV's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivoryon Therapeutics NV Total Liabilities Chart

Vivoryon Therapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.96 4.87 4.55 3.40 2.79

Vivoryon Therapeutics NV Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.55 3.01 3.40 3.24 2.79
LTS:0R3M
33GF Score
Vivoryon Therapeutics NV LTS:0R3M
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivoryon Therapeutics NV Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Vivoryon Therapeutics NV's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.837+(0.044+0.678
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+1.232+0)
=2.79

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=7.518-4.727
=2.79

Vivoryon Therapeutics NV's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.837+(0.044+0.678
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+1.232+0)
=2.79

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=7.518-4.727
=2.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €2.79 Mil mean?
Vivoryon Therapeutics NV (LTS:0R3M) has a Total Liabilities of €2.79 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Vivoryon Therapeutics NV and its competitors.
Is Vivoryon Therapeutics NV's Total Liabilities too high?
Vivoryon Therapeutics NV's current Total Liabilities is €2.79 Mil. Overall, Vivoryon Therapeutics NV has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Vivoryon Therapeutics NV's Total Liabilities compare to VRTX and REGN?
Vivoryon Therapeutics NV's Total Liabilities of €2.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Vivoryon Therapeutics NV and its competitors. Vivoryon Therapeutics NV's current Total Liabilities is €2.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivoryon Therapeutics NV stock overvalued right now?
Vivoryon Therapeutics NV (LTS:0R3M) has a current Total Liabilities of €2.79 Mil. The current Total Liabilities is €2.79 Mil. Vivoryon Therapeutics NV's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Vivoryon Therapeutics NV (LTS:0R3M), the current Total Liabilities is €2.79 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vivoryon Therapeutics NV Business Description

Address Weinbergweg 22, Halle, SN, DEU, 06120
Vivoryon Therapeutics NV is a clinical-stage biopharmaceutical company focused on discovering, developing, and potentially commercializing small-molecule-based medicines that modulate the activity and stability of pathologically altered proteins. Vivoryon is currently focused on developing treatments for chronic kidney disease (CKD), and more precisely, is initially targeting stage 3b and worse diabetic kidney disease (DKD). Its product pipeline includes various drug candidates, including varoglutamstat (PQ912), VY2149, and NCE, as potential treatments for chronic kidney disease (CKD), and more precisely, are initially targeting stage 3b and worse diabetic kidney disease (DKD). The company is also pursuing antibody-based approaches for Alzheimer's disease.
33GF Score

Get the complete analysis for LTS:0R3M

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.21
Price